"A Bit of a Surprise": Kardigan's Tonlamarsen Shows No Blood Pressure Benefit from Repeat Dosing in Phase 2 Trial on March 30, 2026 Angiotensinogen Blood Pressure Hypertensive disease Kardigan KARDINAL trial Phase 2 tonlamarsen +
AstraZeneca Makes Strong Case for Baxdrostat with Detailed 24-Hour Data in Resistant Hypertension Trial on November 10, 2025 24-Hour Data aldosterone synthase inhibitor AstraZeneca baxdrostat Blood Pressure blood pressure ambulatory Phase 3 Clinical Trials Resistant hypertensive disorder safety profile +